What Sets Theralase Technologies’ ($TLT.V | $TLTFF) Ruvidar® Apart in Bladder Cancer Treatment

Podcast: Stocks To Watch · Global One Media Group

Opublikowano: 2026-09-04

This interview is disseminated on behalf of Theralase Technologies Inc. Theralase Technologies Inc. (TSXV: TLT | OTCQB: TLTFF) Chairman, President, and CEO Roger Dumoulin-White, B.Sc, P. Eng. discusses the company’s clinical-stage cancer treatment technology and its development for patients with BCG-unresponsive non-muscle invasive bladder cancer. The interview covers interim Phase II clinical study results for Ruvidar®, including response durability and safety, as well as the potential advantages of Theralase’s drug and proprietary light activation system. Learn more: https://theralase.com/ Watch the full YouTube interview here: https://www.youtube.com/watch?v=sb...